查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1628893

卡培他濱市場，按藥物類型、適應症、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Capecitabine Market, By Drug Type, By Indication, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年卡培他濱市場規模為4.159億美元，2024年至2032年複合年成長率為5.50%。

卡培他濱市場-市場動態

癌症發生率上升

癌細胞通常需要產生和固定 DNA。結果，癌症擴散到身體的其他部位。為了阻止癌細胞產生和修復 DNA，必須使用卡培他濱。推動卡培他濱使用的主要因素之一是癌症（包括肺癌、乳癌和其他形式）發生率的上升，以及癌症治療藥物研發（R＆D）的需求不斷成長。例如，全球癌症觀察站最近發布的資料顯示，2020年全球報告了19,292,789例新癌症病例。其中，大腸直腸癌佔10%，攝護腺癌佔7.3%，胃癌佔5.6%。為了阻止癌症擴散到重要的身體部位，隨著全球癌症病例數量的增加，卡培他濱變得越來越必要。因此，這有助於市場的擴大。

卡培他濱市場 - 主要見解

根據我們的研究分析師分享的分析，全球卡培他濱市場預計在預測期內（2024-2032）每年將以 5.50% 左右的複合年成長率成長

根據藥物類型細分，預計品牌類別將在 2023 年顯示最大的卡培他濱市場佔有率

根據適應症細分，乳癌是2023年的主導細分市場

按地區分類，北美是 2023 年的主要收入來源

卡培他濱市場-細分分析：

全球卡培他濱市場根據藥物類型、適應症、最終用戶和地區進行細分。

適應症細分為乳癌、胰臟癌、大腸癌、胃癌等幾類。 2023年，乳癌細分市場在卡培他濱市場中佔據最大的市場佔有率。醫療機構使用卡培他濱治療先前治療後復發的乳癌，並已進展到頸部、胸部和其他區域周圍的淋巴結和組織。卡培他濱也用於治療早期三陰性乳癌。例如，在歐洲男性人口中，發現了 2,339,617 例新病例。 2020年，乳癌佔歐洲診斷的所有癌症病例的12.07%，成為最常見的癌症類型。因此，隨著乳癌病例數的增加，對卡培他濱阻止乳癌擴散的需求也增加。由於這一重要因素，市場正在擴大。

最終用戶市場分為多個類別，例如醫院、專科診所、家庭護理等。 2023年，醫院細分市場在卡培他濱市場中佔據最大的市場佔有率。許多癌症化療方案的關鍵要素是卡培他濱。因此，卡培他濱在醫院用於治療多種癌症，如大腸癌、晚期和轉移性乳癌等。

卡培他濱市場-地理洞察

從地理來看，卡培他濱市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

2023年，北美在卡培他濱產業中佔據最大的市場佔有率。例如，美國癌症協會估計，美國每年發現 800 至 900 例骨肉瘤（一種影響骨骼的癌症）新病例，其中一半病例發生在青少年身上。因此，北美不斷成長的癌症病例正在支持該地區卡培他濱市場的擴張。

此外，由於醫療保健成本上升、醫療保健服務範圍擴大以及癌症發病率上升，卡培他濱市場在亞太地區正在迅速擴張。由於這些地區的政府和醫療保健專業人員意識到卡培他濱等口服化療藥物對於提高患者便利性和治療效果的重要性，因此在臨床實踐中得到越來越廣泛的使用。

卡培他濱市場-競爭格局：

卡培他濱市場競爭極為激烈，有許多大公司以及大量中小企業，如 Teva Pharmaceutical Industries Ltd.、F. Hoffmann-La Roche Ltd.、Mylan NV、Pfizer Inc.（美國） ）、賽諾菲（法國）等。這些企業由於其廣泛的產品和分銷系統而擁有強大的研發能力和重要的市場佔有率。該市場的競爭非常激烈，企業專注於擴大產品線並透過合作、併購和收購來獲得市場佔有率。例如，生產該藥物的印度公司 Dr. Reddy's Laboratories Ltd. 於 2021 年 2 月在美國市場推出了希羅達（卡培他濱）片劑的學名藥。因此，由於全球市場產品供應的增加，卡培他濱市場正在成長。

最新進展：

2023 年 1 月：德國製藥公司 Cheplapharm Arzneimittel GmbH 以未公開的金額從 F. Hoffmann-La Roche AG 購買了希羅達（卡培他濱）在中國的行銷權。 Cheplapharma 希望透過此次收購增加其在製藥業的市場佔有率並強化其癌症產品組合。位於瑞士的製藥公司 F. Hoffmann-La Roche AG 生產口服化療藥物卡培他濱，也稱為希羅達。

2022 年 12 月：Shilpa Medicare 推出了一種 90 秒溶解的卡培他濱分散丸，用於治療大腸直腸癌和轉移性乳癌。透過增加市場收入，該產品的推出有助於公司實現產品多元化。

目錄

第 1 章：卡培他濱市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 卡培他濱市場片段（依藥物類型）
    • 卡培他濱市場片段（按適應症）
    • 最終用戶的卡培他濱市場片段
    • 卡培他濱市場片段（依國家）
    • 卡培他濱市場片段（按地區）
  • 競爭洞察

第 3 章：卡培他濱主要市場趨勢

  • 卡培他濱市場促進因素
    • 市場促進因素的影響分析
  • 卡培他濱市場限制
    • 市場限制影響分析
  • 卡培他濱市場機會
  • 卡培他濱市場未來趨勢

第 4 章：卡培他濱產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：卡培他濱市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：卡培他濱市場格局

  • 2023 年卡培他濱市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：卡培他濱市場 - 按藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 通用的
    • 品牌化

第 8 章：卡培他濱市場 - 依適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 乳癌
    • 胰腺癌
    • 大腸直腸癌
    • 胃癌
    • 其他

第 9 章：卡培他濱市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 專科診所
    • 居家護理
    • 其他

第 10 章：卡培他濱市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 卡培他濱北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類型）
    • 北美市場規模和預測（按指標）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 卡培他濱歐洲主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類型）
    • 歐洲市場規模與預測（按指標）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 卡培他濱亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類型）
    • 亞太地區市場規模與預測（依指標）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 卡培他濱拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類型）
    • 拉丁美洲市場規模與預測（按指標）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 卡培他濱中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類型）
    • 中東和非洲市場規模及預測（依指標）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析-卡培他濱產業

  • 競爭儀表板
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.(Israel)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Mylan NV (US)
    • Pfizer Inc. (US.)
    • Sanofi (France)
    • Bayer AG (Germany)
    • Lilly (US.)
    • Sun Pharmaceutical Industries Ltd. (India)
    • GSK plc (UK.)
    • Novartis AG (Switzerland)
    • Merck & Co., Inc. (US.)
    • Alkem Labs Ltd (India)
    • Aurobindo Pharma (India)
    • Lupin (India)
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4422

REPORT HIGHLIGHT

Capecitabine Market size was valued at USD 415.9 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

Capecitabine is an oral chemotherapy medication, which is used to treat a number of malignancies, such as those of the breast, colon, and rectal region. It is a member of the antimetabolite medication class, which inhibits the development and transmission of cancer cells. Since capecitabine is a prodrug, the body transforms it into 5-fluorouracil (5-FU), which is its active form. After being transformed, 5-FU stops cancer cells from making DNA and RNA, which eventually kills the cells. Capecitabine, which is typically given as pills, is taken orally as opposed to intravenously as conventional chemotherapy medications. The increase in the older population, the rise in cancer prevalence, and the intense research and development efforts to assess novel pharmacological uses of capecitabine are the main factors propelling the market's expansion. Additionally, the market is rising due to factors like the expansion of new cancer institutions, increased expenditure in cancer research, and others that are driving up demand for capecitabine. Furthermore, the market will rise even more during the projection period due to the growing development of new capecitabine product categories.

Capecitabine Market- Market Dynamics

Rising Incidence of Cancer

It is often necessary for the cancer cells to produce and fix DNA. As a result, cancer spreads to other body parts. In order to stop cancer cells from creating and repairing DNA, capecitabine must be used. One of the main factors propelling the use of capecitabine is the rising incidence of cancer, including lung, breast, and other forms, as well as the growing need for pharmaceutical research and development (R&D) for cancer therapy. For instance, the Global Cancer Observatory recently released data showing that 19,292,789 new cases of cancer were reported worldwide in 2020. With 11.7% of all cases, breast cancer was the most frequent type of cancer in 2020. Lung cancer came in second with 11.4%, colorectum cancer with 10%, prostate cancer with 7.3%, and stomach cancer with 5.6%. In order to stop cancer from spreading to important body parts, capecitabine is becoming more and more necessary as the number of cancer cases worldwide rises. Consequently, this is contributing to the expansion of the market.

Capecitabine Market- Key Insights

As per the analysis shared by our research analyst, the global Capecitabine Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on drug type segmentation, the branded category was predicted to show maximum Capecitabine Market share in the year 2023

Based on indication segmentation, the breast cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Capecitabine Market- Segmentation Analysis:

The Global Capecitabine Market is segmented on the basis of Drug Type, Indication, End-user, and Region.

The indication segment is divided into several categories, including Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, and Others. In 2023, the breast cancer segment held the largest market share in the capecitabine market. Healthcare facilities use capecitabine to treat breast cancer that has returned after prior treatment and has progressed to the lymph nodes and tissues surrounding the neck, chest, and other areas. Capecitabine is also used to treat triple-negative breast cancer in its early stages. For instance, in the male population of Europe, 2,339,617 new cases were detected. Breast cancer accounted for 12.07% of all cancer cases diagnosed in Europe in 2020, making it the most frequent kind. Therefore, the need for capecitabine to stop the spread of breast cancer is growing as the number of cases of the disease rises. The market is expanding as a result of this important element.

The end-user market is divided into various categories, such as Hospitals, Specialty Clinics, Homecare, and Others. The hospitals' segment held the largest market share in the capecitabine market in 2023. Several international governmental authorities, including the European Union and the US Food and Drug Administration (FDA), have approved the use of capecitabine. A key element of many cancer chemotherapy regimens is capecitabine. As a result, capecitabine is used in hospitals to treat a variety of cancers, such as colorectal cancer, advanced and metastatic breast cancer, and others.

Capecitabine Market- Geographical Insights

Geographically, the Capecitabine Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the largest market share in the capecitabine industry in 2023. The rising incidence of cancer cases, the increased creation of new products, and other factors are blamed for this trend. For instance, the American Cancer Society estimates that between 800 and 900 new cases of osteosarcoma, a bone-affecting cancer, are discovered in the US annually, with half of those cases occurring in adolescents and teenagers. Consequently, the growing number of cancer cases in North America is supporting the expansion of the capecitabine market in the area.

In addition, the market for capecitabine is expanding quickly in Asia-Pacific due to the rising healthcare costs, expanded access to healthcare services, and rising cancer incidence rates. Oral chemotherapy medications like capecitabine are becoming more widely used in clinical practice as a result of governments and healthcare professionals in these areas realizing how important they are for enhancing patient convenience and treatment outcomes.

Capecitabine Market- Competitive Landscape:

The market for capecitabine is extremely competitive, with many major companies as well as a huge number of small and medium-sized businesses such as Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc. (US), Sanofi (France), and others. These businesses have robust R&D capacities and a significant market presence due to their wide range of products and distribution systems. The market is notoriously competitive, with businesses concentrating on growing their product lines and gaining market share through partnerships, mergers, and acquisitions. For instance, the generic form of Xeloda (capecitabine) tablets was introduced in the US market in February 2021 by Dr. Reddy's Laboratories Ltd., an Indian company that manufactures the medication. Therefore, the capecitabine market is growing as a result of the increase in product offerings in the global market.

Recent Developments:

January 2023: For an undisclosed sum, Cheplapharm Arzneimittel GmbH, a pharmaceutical firm based in Germany, purchased the marketing rights to Xeloda (capecitabin) in China from F. Hoffmann-La Roche AG. Through the acquisition, Cheplapharma hopes to increase its market share in the pharmaceutical industry and fortify its cancer portfolio. The pharmaceutical business F. Hoffmann-La Roche AG, situated in Switzerland, manufactures the oral chemotherapy medication capecitabine, also known as Xeloda.

December 2022: A 90-second-dissolving Capecitabine dispersible pill for the treatment of colorectal and metastatic breast cancer was introduced by Shilpa Medicare. By increasing market revenue, the product's launch aids the corporation in diversifying its offerings.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAPECITABINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Teva Pharmaceutical Industries Ltd.(Israel)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (US.)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Lilly (US.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • GSK plc (UK.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (US.)
  • Alkem Labs Ltd (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Others

GLOBAL CAPECITABINE MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Generic
  • Branded

GLOBAL CAPECITABINE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Others

GLOBAL CAPECITABINE MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL CAPECITABINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The US.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Capecitabine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Capecitabine Market Snippet by Drug Type
    • 2.1.2. Capecitabine Market Snippet by Indication
    • 2.1.3. Capecitabine Market Snippet by End-user
    • 2.1.4. Capecitabine Market Snippet by Country
    • 2.1.5. Capecitabine Market Snippet by Region
  • 2.2. Competitive Insights

3. Capecitabine Key Market Trends

  • 3.1. Capecitabine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Capecitabine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Capecitabine Market Opportunities
  • 3.4. Capecitabine Market Future Trends

4. Capecitabine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Capecitabine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Capecitabine Market Landscape

  • 6.1. Capecitabine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Capecitabine Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Generic
    • 7.1.3. Branded

8. Capecitabine Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Pancreatic Cancer
    • 8.1.4. Colorectal Cancer
    • 8.1.5. Gastric Cancer
    • 8.1.6. Others

9. Capecitabine Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Homecare
    • 9.1.5. Others

10. Capecitabine Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Capecitabine Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Capecitabine Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Capecitabine Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Capecitabine Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Capecitabine Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Capecitabine Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceutical Industries Ltd.(Israel)
    • 11.2.2. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 11.2.3. Mylan N.V. (U.S.)
    • 11.2.4. Pfizer Inc. (US.)
    • 11.2.5. Sanofi (France)
    • 11.2.6. Bayer AG (Germany)
    • 11.2.7. Lilly (US.)
    • 11.2.8. Sun Pharmaceutical Industries Ltd. (India)
    • 11.2.9. GSK plc (UK.)
    • 11.2.10. Novartis AG (Switzerland)
    • 11.2.11. Merck & Co., Inc. (US.)
    • 11.2.12. Alkem Labs Ltd (India)
    • 11.2.13. Aurobindo Pharma (India)
    • 11.2.14. Lupin (India)
    • 11.2.15. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us